Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 9/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5368083 | 0.82 | FBP1 (0.65) | FBP1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4956466 | 0.79 | FBP1 (0.64) | FBP1ADORA2AADORA1ADORA3FGFR1 | |
| SCHEMBL5373101 | 0.76 | FBP1 (0.62) | FBP1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4909033 | 0.71 | ADORA2A (0.59) | FBP1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4954814 | 0.66 | FBP1 (0.49) | FBP1ADORA2AADORA1ADORA2BSLC22A6 | |
| SCHEMBL5376477 | 0.66 | FBP1 (0.76) | FBP1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL9185744 | 0.65 | SLC22A6 (0.62) | FBP1ADORA2AADORA1FGFR1SLC22A6 | |
| Adefovir SCHEMBL29365535 | 0.65 | FGFR1 (1.00) | ADORA2AADORA1ADORA2BFGFR1SLC22A6 | |
| Adefovir SCHEMBL49373 | 0.65 | FGFR1 (1.00) | ADORA2AADORA1ADORA2BFGFR1SLC22A6 | |
| SCHEMBL8418890 | 0.64 | ADORA2A (0.61) | FBP1ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285543-B2 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | DANG QUN | 2005-12-15 | — | — | US | disclosed |
| US-6967193-B1 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6284748-B1 | ANTIDIABETIC AGENT | METABASIS THERAPEUTICS, INC. | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | FBP1, PNP, PPA1 | FBP1 1/4885ADORA2A 319/4885ADORA1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.